Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Asset Writedowns and Impairment (2024 - 2025)

Historic Asset Writedowns and Impairment for Ptc Therapeutics (PTCT) over the last 3 years, with Q3 2025 value amounting to $400000.0.

  • Ptc Therapeutics' Asset Writedowns and Impairment fell 6965.1% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $161.3 million, marking a year-over-year increase of 1052700.92%. This contributed to the annual value of $159.5 million for FY2024, which is 2674.56% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Asset Writedowns and Impairment of $400000.0 as of Q3 2025, which was down 6965.1% from $100000.0 recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Asset Writedowns and Impairment high stood at $217.8 million for Q2 2023, and its period low was $100000.0 during Q2 2025.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $859000.0 (2024), whereas its average is $63.2 million.
  • In the last 5 years, Ptc Therapeutics' Asset Writedowns and Impairment plummeted by 9990.82% in 2024 and then tumbled by 5000.0% in 2025.
  • Ptc Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $217.8 million in 2023, then dropped by 26.77% to $159.5 million in 2024, then crashed by 99.75% to $400000.0 in 2025.
  • Its Asset Writedowns and Impairment was $400000.0 in Q3 2025, compared to $100000.0 in Q2 2025 and $159.5 million in Q4 2024.